Tags

Type your tag names separated by a space and hit enter

Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients.
Eur Neuropsychopharmacol. 2008 Feb; 18(2):141-6.EN

Abstract

Pindolol, a 5-HT1A autoreceptor antagonist, given in combination with selective serotonin reuptake inhibitors (SSRIs), may enhance and/or accelerate the therapeutic efficacy of SSRIs. Fifty patients, meeting ICD-10 criteria for major depressive disorder or bipolar depression, were enrolled in our randomized, placebo-controlled, double-blind trial. One group received paroxetine plus pindolol (2.5 mg t.i.d.), and the other group received paroxetine plus placebo. The proportion of patients with sustained response (>or=50% reduction of baseline HAM-D 17 score maintained until the endpoint; p=0.252) and the proportion of patients with remission (HAM-D 17 <or=8 at last visit; p=0.769) did not differ significantly between the two treatment groups. However, a significantly greater proportion of patients who were not previously treated with antidepressants (n=15; p=0.041) and of patients with bipolar depression (n=11; p=0.015) had a sustained response in the paroxetine plus pindolol group compared to the paroxetine plus placebo group; furthermore there was a trend for first episode depressed patients to have a greater response in the paroxetine plus pindolol group (n=12; p=0.071). Summarizing, the entire study population showed no antidepressive benefit from pindolol augmentation. Nevertheless patients with bipolar depression irrespective of previous treatments and duration of illness, and unipolar patients not previously treated demonstrated a significant benefit from pindolol augmentation.

Authors+Show Affiliations

University Clinics of Psychiatry and Psychotherapy I, Paracelsus Medical University, Ignaz-Harrer-Str. 79, 5020 Salzburg, Austria. c.geretsegger@salk.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18054209

Citation

Geretsegger, Christian, et al. "Paroxetine With Pindolol Augmentation: a Double-blind, Randomized, Placebo-controlled Study in Depressed In-patients." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 18, no. 2, 2008, pp. 141-6.
Geretsegger C, Bitterlich W, Stelzig R, et al. Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. Eur Neuropsychopharmacol. 2008;18(2):141-6.
Geretsegger, C., Bitterlich, W., Stelzig, R., Stuppaeck, C., Bondy, B., & Aichhorn, W. (2008). Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 18(2), 141-6.
Geretsegger C, et al. Paroxetine With Pindolol Augmentation: a Double-blind, Randomized, Placebo-controlled Study in Depressed In-patients. Eur Neuropsychopharmacol. 2008;18(2):141-6. PubMed PMID: 18054209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. AU - Geretsegger,Christian, AU - Bitterlich,Waltraud, AU - Stelzig,Renate, AU - Stuppaeck,Christoph, AU - Bondy,Brigitta, AU - Aichhorn,Wolfgang, Y1 - 2007/11/28/ PY - 2007/01/02/received PY - 2007/08/31/revised PY - 2007/09/21/accepted PY - 2007/12/7/pubmed PY - 2008/4/19/medline PY - 2007/12/7/entrez SP - 141 EP - 6 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 18 IS - 2 N2 - Pindolol, a 5-HT1A autoreceptor antagonist, given in combination with selective serotonin reuptake inhibitors (SSRIs), may enhance and/or accelerate the therapeutic efficacy of SSRIs. Fifty patients, meeting ICD-10 criteria for major depressive disorder or bipolar depression, were enrolled in our randomized, placebo-controlled, double-blind trial. One group received paroxetine plus pindolol (2.5 mg t.i.d.), and the other group received paroxetine plus placebo. The proportion of patients with sustained response (>or=50% reduction of baseline HAM-D 17 score maintained until the endpoint; p=0.252) and the proportion of patients with remission (HAM-D 17 <or=8 at last visit; p=0.769) did not differ significantly between the two treatment groups. However, a significantly greater proportion of patients who were not previously treated with antidepressants (n=15; p=0.041) and of patients with bipolar depression (n=11; p=0.015) had a sustained response in the paroxetine plus pindolol group compared to the paroxetine plus placebo group; furthermore there was a trend for first episode depressed patients to have a greater response in the paroxetine plus pindolol group (n=12; p=0.071). Summarizing, the entire study population showed no antidepressive benefit from pindolol augmentation. Nevertheless patients with bipolar depression irrespective of previous treatments and duration of illness, and unipolar patients not previously treated demonstrated a significant benefit from pindolol augmentation. SN - 0924-977X UR - https://www.unboundmedicine.com/medline/citation/18054209/Paroxetine_with_pindolol_augmentation:_a_double_blind_randomized_placebo_controlled_study_in_depressed_in_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-977X(07)00187-3 DB - PRIME DP - Unbound Medicine ER -